Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

BACKGROUND: Metaplastic breast carcinomas are rare and carry poor prognoses. They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy. Prolonged treatment with dabrafenib and trametinib is a therapy for malignant melanoma that improves the progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Takuji, Noguchi, Emi, Yoshida, Masayuki, Mori, Taisuke, Tanioka, Maki, Sudo, Kazuki, Shimomura, Akihiko, Yonemori, Kan, Fujiwara, Yasuhiro, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079252/
https://www.ncbi.nlm.nih.gov/pubmed/32206360
http://dx.doi.org/10.1155/2020/2518383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079252/
https://www.ncbi.nlm.nih.gov/pubmed/32206360
http://dx.doi.org/10.1155/2020/2518383

Ejemplares similares